Takeda Pharmaceutical Co. $TAK Stake Lifted by Vise Technologies Inc.

Vise Technologies Inc. grew its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 52.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 180,092 shares of the company’s stock after acquiring an additional 61,968 shares during the period. Vise Technologies Inc.’s holdings in Takeda Pharmaceutical were worth $3,276,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of TAK. Renaissance Technologies LLC raised its holdings in shares of Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares during the period. Quantinno Capital Management LP lifted its stake in Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after purchasing an additional 219,999 shares during the last quarter. Royal Bank of Canada lifted its stake in Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after purchasing an additional 60,725 shares during the last quarter. Bleakley Financial Group LLC lifted its stake in Takeda Pharmaceutical by 19.0% in the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock valued at $7,993,000 after purchasing an additional 68,844 shares during the last quarter. Finally, QRG Capital Management Inc. grew its holdings in Takeda Pharmaceutical by 1.4% during the second quarter. QRG Capital Management Inc. now owns 372,752 shares of the company’s stock valued at $5,975,000 after purchasing an additional 5,064 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Weiss Ratings raised Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday. Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy”.

Insider Buying and Selling

In related news, insider Lauren Duprey sold 34,535 shares of Takeda Pharmaceutical stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the transaction, the insider directly owned 191,522 shares in the company, valued at approximately $3,550,817.88. The trade was a 15.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Deidre Greenway sold 12,980 shares of Takeda Pharmaceutical stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $18.11, for a total transaction of $235,067.80. Following the completion of the transaction, the insider owned 40,049 shares of the company’s stock, valued at $725,287.39. This represents a 24.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 627,457 shares of company stock valued at $10,981,175. Corporate insiders own 0.04% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $21.07 on Thursday. The company has a quick ratio of 0.60, a current ratio of 1.15 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $67.50 billion, a PE ratio of 11.86 and a beta of -0.02. Takeda Pharmaceutical Co. has a twelve month low of $13.49 and a twelve month high of $21.22. The company has a 50-day moving average price of $19.01 and a two-hundred day moving average price of $17.62.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.